Aims-To evaluate the behaviour ofplasma endothelin-1 in patients with chronic hypoxia. Methods-Fifteen male patients (mean age 52-1 + 3-1 years) with mild chronic obstructive pulmonary disease (COPD) were studied. Twelve healthy men (mean age 48 3 +5 54 years) served as controls. Both patients and controls underwent standard pulmonary function tests, echocardiographic evaluation, and arterial blood gas evaluation. Blood samples for endothelin-l assay were taken from a previously incannulated antecubital vein after 60 minutes of rest in the supine position. 
48 3 +5 54 years) served as controls. Both patients and controls underwent standard pulmonary function tests, echocardiographic evaluation, and arterial blood gas evaluation. Blood samples for endothelin-l assay were taken from a previously incannulated antecubital vein after 60 minutes of rest in the supine position. Endothelin Arterial blood was collected in heparinised syringes from a brachial artery. Gas evaluations were performed by a standard laboratory blood gas analyser (ABL 510 Radiometer, Copenhagen, Denmark).
BLOOD PRESSURE AND ECHOCARDIOGRAPHIC EVALUATIONS
Systemic arterial blood pressure and heart rate were measured at 10 minute intervals using an automatic sphygmomanometer (Nippon Colin). Mean blood pressure (MBP; mmHg) was evaluated using the formula:
where DBP is the diastolic and SBP the systolic blood pressure. Echocardiographic studies were performed using commercially available equipment with Serum creatinine (pLmoIl) 8-24 mmHg) . The left ventricular ejection fraction was slightly reduced (65-6+8-9%), although it was greater than 50% in all patients. The mean circulating endothelin-1 concentration was 1-22 + 0-36 pg/ml (fig 1) . A negative correlation was found between plasma endothelin-1 concentrations and PaO2 (r= -0-614; p<002) (fig 2A) . However, plasma endothelin-1 concentrations directly correlated with the degree of arterial pulmonary pressure (r=0-571; p<0-03) ( fig 2B) . It was also interesting to note that pulmonary pressure negatively correlated with PaO2 values (r= -0-073; p<0-003). No other correlations were found. In particular, circulating endothelin-1 concentrations did not correlate with blood pressure, plasma glucose, or fasting insulin and lipid concentrations.
CONTROLS
The controls had normal values for glucose and lipid metabolism, and renal function (table  1) . Cardiac and respiratory parameters (table  2) were also normal. In particular, the controls had normal arterial gas values (PaO2= 83-8 + 2-7 mmHg; PaCO2 = 36-7 + 3-1 mmHg) and oxygen saturation (91-3+3-8% saturated haemoglobin). Plasma endothelin-1 concentrations were 0-57+0-10pg/ml (fig 1) and did not correlate with PaO2. Arterial pulmonary pressure was 10-4 + 2-7 mmHg and did not correlate with either circulating endothelin-1 concentrations or PaO2. Plasma endothelin-1 concentrations also did not correlate with the other parameters evaluated, such as plasma glucose and insulin concentrations.
COMPARISON BETWEEN GROUPS
When intergroup comparisons were performed, some significant differences were noted. Cir-2-2FB Pulmonary pressure (mmHg) Figure 2 In patients with COPD (n= 15) plasma endothelin-1 (ET-1) concentrations were negatively correlated with (A) arterial PaO2 but were direcdy correlated with (B) arterial pulmonary pressure.
PaO2 (mmHg)
t-culating endothelin-1 concentrations were significantly higher in patients with COPD than in controls (p<0-001) (fig 1) , with very little overlap between the two groups. Indeed, in patients with COPD plasma endothelin-1 concentrations ranged from 0 54 to 2 10pg/ml, whereas in controls these ranged from 0-42 to 0-72 pg/ml (fig 1) . As a consequence, only two patients had plasma endothelin-1 concentrations within the normal range, whereas the remaining 13 had endothelin-1 concentrations two-to fourfold higher than those in controls.
As expected, both FEV, and FEV1/vital capacity were lower in the patients than controls (p<0001 and p<00005, respectively) (table 2), as was PaO2 (p<0 0005). Systolic, diastolic, and mean blood pressure values were similar in both groups (table 1) ; however, mean arterial pulmonary pressure was significantly higher in patients than in controls (p<00001), but remained within the normal range in both groups. The left ventricular ejection fraction, however, was higher in controls (p<0-01) ( Our results demonstrate that circulating endothelin-1 concentrations were significantly increased in hypoxemic patients compared with healthy subjects (p<0-001). Moreover, endothelin-1 concentrations were negatively correlated with PaO2 and directly correlated with arterial pulmonary pressure. The latter was higher (p<0-001) in hypoxemic patients than in the control subjects, being directly correlated with PaO2 in the former only.
Our results concur with previous findings in the rat,25 of increased synthesis of endothelin-1 in response to hypoxia. The intracellular pathway by which hypoxia modulates endothelin-1 synthesis in vascular endothelial cells is not known, but previous findings in cultured human endothelial cells suggested that oxygen may act at the nuclear level by increasing preproendothelin-1 gene expression and consequently preproendothelin-1 mRNA production.'4 Action at the post-transcriptional level is unlikely as endothelin-1 release requires de novo protein synthesis.'"0 Our study extends the data reported by Giussani et all5 showing that chronic hypoxia is a major determinant of circulating endothelin-1 concentrations in patients with respiratory failure, and suggesting that it may be an important regulator of the vascular tone in the pulmonary circulation.
In this regard, hypoxia is already regarded as a possible pathogenic factor in the development of pulmonary hypertension,26 but the possible role of hypoxia mediated endothelin-1 release has never been investigated.
However, Adnot et al23 have recently demonstrated that endothelin-1 induces greater pulmonary vasoconstriction in rats with chronic hypoxia compared with control rats. Moreover, Giaid et a!27 reported elevated endothelin-1 gene expression in vascular endothelial cells derived from the lungs of patients with both primary and secondary forms of pulmonary hypertension. In keeping with these data, we showed that pulmonary pressure values were significantly correlated with plasma endothelin-1 concentrations, suggesting that the peptide may act as a potent vasoconstrictor for the lung vascular bed, at least in conditions associated with a significant increase in its circulating concentrations. In agreement with this interpretation, De Nucci et al7 have already demonstrated the high avidity of the pulmonary vasculature for circulating endothelin-1, and both endothelial and vascular smooth muscle cells receptors28 have been demonstrated in the lung. In contrast to this hypothesis, Deleuze et al29 showed that endothelin-1 induced dose dependent vasodilation in the pulmonary circulation of calves breathing in hypoxic conditions. In particular, low doses of endothelin-1 induced a mild decrease in the pulmonary artery pressure, whereas high doses caused pulmonary vasodilation and systemic vasoconstriction. Thus, the action of endothelin-1 may differ in pulmonary and systemic circulations, refuting the suggested pathogenic role for endothelin-1 in the development of pulmonary hypertension. Nevertheless, the data from Deleuze et al29 may simply reflect the different pressures in the two vascular beds-the pulmonary circulation is a low pres-sure, low resistance vascular bed, where circulating endothelin-1 is cleared rapidly.7 Therefore, endothelin-1 could not constrict pulmonary vessels in vivo because of the presence of highly stimulated endothelin-B receptors on the luminal endothelial surface,' 3 10 and the consequent endothelin-B receptor mediated release of prostacyclin and nitric oxide.7 Endothelin-1 does not readily penetrate the external endothelial cell membrane29 and therefore circulating endothelin-1 could not bind to endothelin-A receptors, which mediate vasoconstriction and are expressed by vascular smooth muscle cells lying beneath the endothelium."°Therefore, it could be hypothesised that hypoxia might alter vascular reactivity to various agents, acting either in a paracrine or an autocrine manner and interacting at the vascular level. Locally, the prevalence of constrictor agents and/or a decrease in vasodilator concentrations could lead to the development of pulmonary hypertension. In this context, the increase in circulating endothelin-1 concentrations could reflect an increase in the intracellular production of endothelin-I and its subsequent release. According to this hypothesis, about 80% of newly generated endothelin-1 is secreted through the basolateral membrane, and only 20% is released into the blood.30 Perhaps, therefore, circulating endothelin-1 should be regarded as a marker for pulmonary hypertension rather than as a cause of lung disease.
In conclusion, the present study demonstrates for the first time that circulating endothelin-1 concentrations are increased in patients with chronic hypoxia. In spite of the increase in plasma endothelin-1 concentrations patients did not have concomitant systemic hypertension, renal damage, or cardiovascular disease. Thus, it is likely that endothelin-1, in conjunction with other endothelium derived vasoactive factors-for example, prostaglandin I2 and endothelium derived relaxing factor, acts in a autocrine/paracrine manner rather than in an endocrine one. The direct correlation between plasma endothelin-1 concentrations and pulmonary pressure values suggests that endothelin-1 may exert its vasoconstrictive action in the pulmonary vascular bed. Alternatively, it is possible that circulating endothelin-1 may have not a significant effect on the vascular tone in lung arteries, and may be a marker rather than a determinant of pulmonary disease associated with vasoconstriction.
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